| 29.25 0.67 (2.34%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 34.95 | 1-year : | 40.83 |
| Resists | First : | 29.93 | Second : | 34.95 |
| Pivot price | 27.69 |
|||
| Supports | First : | 27.52 | Second : | 26.04 |
| MAs | MA(5) : | 28.23 |
MA(20) : | 27.86 |
| MA(100) : | 32.71  |
MA(250) : | 33.28 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 78.8 |
D(3) : | 62.8 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 46 | Low : | 22.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AGIO ] has closed above the upper band by 5.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 29.33 - 29.47 | 29.47 - 29.6 |
| Low: | 27.89 - 28.05 | 28.05 - 28.2 |
| Close: | 28.98 - 29.25 | 29.25 - 29.5 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Sat, 14 Feb 2026
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress - Yahoo Finance
Fri, 13 Feb 2026
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Fri, 13 Feb 2026
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Thu, 12 Feb 2026
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight - GuruFocus
Thu, 12 Feb 2026
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Thu, 12 Feb 2026
Agios Pharmaceuticals: Q4 Earnings Snapshot - KVUE
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 103.9 (%) |
| Shares Short | 7,450 (K) |
| Shares Short P.Month | 6,130 (K) |
| EPS | -7.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.04 |
| Profit Margin | 0 % |
| Operating Margin | -907.4 % |
| Return on Assets (ttm) | -18.8 % |
| Return on Equity (ttm) | -27.6 % |
| Qtrly Rev. Growth | 43.7 % |
| Gross Profit (p.s.) | -5.07 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | -8.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -410 (M) |
| Levered Free Cash Flow | -314 (M) |
| PE Ratio | -4.18 |
| PEG Ratio | 0 |
| Price to Book value | 1.32 |
| Price to Sales | 38.07 |
| Price to Cash Flow | -4.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|